All In Biotech

Drug Trial Radar · NCT05489211

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

454

Planned (sponsor's estimate)

Start

Sep 6, 2022

Primary completion

Oct 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Conditions

  • Endometrial Cancer
  • Gastric Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Urothelial Cancer
  • Biliary Tract Cancer

Interventions

  • Datopotamab deruxtecan (Dato-DXd)Drug

    Intravenous (IV) Antibody drug conjugate

  • CapecitabineDrug

    Administered orally

  • 5-FluorouracilDrug

    Administered as an IV

  • VolrustomigDrug

    Administered as an IV

  • CarboplatinDrug

    Administered as an IV

  • BevacizumabDrug

    Administered as an IV

  • RilvegostomigDrug

    Administered as an IV

  • Prednisone/ prednisoloneDrug

    Administered orally

  • CisplatinDrug

    Administered as an IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: From baseline to progressive disease or death (approximately 1 year)
  2. The number of subjects with adverse events/serious adverse eventsTime frame: Throughout the treatment and the safety follow-up period 28 [+ 7] days after the discontinuation of all study interventions, except durvalumab, nivolumab, and bevacizumab for which it will be 90 [+ 7] days (approximately 1 year)
  3. PSA50 response (Substudy 3 only)Time frame: From baseline to PSA response evaluated according to the PCWG3 criteria (approximately 1 year)
  4. Progression free survival (PFS) response (Substudy 4C only)Time frame: From baseline to progressive disease or death (approximately 1 year)

Locations

96 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Diego, California · Withdrawn

  • Research Site

    Santa Rosa, California · Recruiting

  • Research Site

    Muncie, Indiana · Withdrawn

  • Research Site

    Kansas City, Kansas · Withdrawn

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Boston, Massachusetts · Completed

  • Research Site

    Grand Rapids, Michigan · Recruiting

  • Research Site

    East Brunswick, New Jersey · Recruiting

  • Research Site

    Albuquerque, New Mexico · Recruiting

  • Research Site

    Commack, New York · Recruiting

  • Research Site

    Cincinnati, Ohio · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Withdrawn

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Withdrawn

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Madison, Wisconsin · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Withdrawn

  • Research Site

    Toronto, Ontario, Canada · Completed

  • Research Site

    Montreal, Quebec, Canada · Withdrawn

  • Research Site

    Montreal, Quebec, Canada · Completed

  • Research Site

    Québec, Quebec, Canada · Active not recruiting

  • Research Site

    Changsha, China · Withdrawn

  • Research Site

    Chongqing, China · Withdrawn

  • Research Site

    Guangzhou, China · Completed

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Guangzhou, China · Withdrawn

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Hefei, China · Withdrawn

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanghai, China · Not yet recruiting

  • Research Site

    Shenyang, China · Withdrawn

  • Research Site

    Wuhan, China · Withdrawn

  • Research Site

    Wuhan, China · Withdrawn

  • Research Site

    Xi'an, China · Withdrawn

  • Research Site

    Zhengzhou, China · Recruiting

  • Research Site

    Bordeaux, France · Recruiting

  • Research Site

    Lyon, France · Recruiting

  • Research Site

    Marseille, France · Withdrawn

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.